Mindbloom’s New Spa-Like Psychedelics Clinic is Located in New York City and Offers Guided Ketamine Therapy
Mindbloom, a guided and legal psychedelic therapy centre, has officially opened its doors on New York City’s famed 5th Avenue. The newly opened centre offers clinician-prescribed and science-based guided ketamine therapy in a modern, spa-like environment. Costs range from between $150 – $250 per session.
Once known as a party drug, Ketamine is now being hailed as a potential miracle medication for conditions such as severe depression, anxiety and PTSD. Research efforts have shown Ketamine to have great potential as an antidepressant due to its fast-acting effects, which may reduce depression and suicidal thoughts within hours.
Following hundreds of private sessions conducted over the past few months, Mindbloom is now extending its clinical protocols to the general public. Designed by well-respected psychedelics expert and psychiatric practitioner, Dr. Casey Paleos, Mindbloom will begin by offering treatments to help address the all-too-common symptoms surrounding depression and anxiety. Additionally, Mindbloom will offer remote, technology-enabled therapy sessions.
“We’re essentially One Medical meets Headspace, but for psychedelic therapy,” says Dylan Beynon, CEO, Mindbloom.
What’s the Patient Process?
All Mindbloom patients are required to undergo a thorough screening before they’re eligible to receive Ketamine therapy. The initial test includes a rigorous psychiatric evaluation led by a clinician. Once greenlit for treatment, patients then receive four one-hour sessions in which FDA-approved Ketamine is administered through sublingual tablets or via intramuscular injection.
Patients are supported during the experience by friendly and experienced guides, and each session concludes with a period of quiet reflection.
As Mindbloom’s board-certified psychiatrist and medical director, Dr. Casey Paleos has spent over ten years researching the health implications of psychedelics such as MDMA, Psilocybin (the psychedelic compound found in magic mushrooms), and Ketamine. After years of clinical and academic study, Dr. Paleos feels strongly about offering psychedelics to patients who qualify.
“It’s a privilege to help bring these cutting edge medicines to the people who need it most,” says Dr. Paleos. “Mindbloom’s therapeutic protocols are science-backed, medically supervised, and expertly designed to help clients achieve optimal wellness and mental health.”
Dylan Beynon, the clinic’s CEO, echoes Dr. Paleos’ sentiment:
“I’ve experienced profound healing and personal growth with ketamine therapy,” says Beynon. “We founded Mindbloom to bring psychedelic medicine out of the shadows and make it an approachable, accessible option for people battling anxiety and depression. Every detail of our first psychedelic therapy center in New York City has been thoughtfully designed to deliver a comfortable, elevated, and inspired client experience.”
Are Psychedelic Clinics the Next Trend?
Mindbloom may be the first, but don’t expect it to be the last.
Just last week, Field Trip Health — a subsidiary of the Field Trip psychedelics company — opened a psychedelic-enhanced psychotherapy clinic in Toronto, Ontario. Similar to Mindbloom, Field Trip Health will deliver psychedelic-enhanced treatments, including through the administration of Ketamine. In addition to their Toronto location, Field Trip Health has plans to open centres in Los Angeles and New York this year, while Mindbloom has plans for additional centres in Los Angeles, Austin, San Francisco, and San Diego.
“The opening of the first Field Trip centre in Toronto represents a pivotal moment in the treatment of depression, anxiety, and PTSD,” says Ronan Levy, Executive Chairman of Field Trip. “It brings psychedelic medicine to the forefront of mental health care and well-being. Our clinic and patient experiences have been designed from the ground up to deliver the best therapeutic outcomes. We believe that psychedelic medicine will fundamentally alter the way mental health challenges are approached globally, and we are happy to be playing an important part of this movement.”
Disclosure: The Cannabis Investor does not hold a position in any of the stocks mentioned in this article.